Beijing
China
Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC) - Clinical Trial Center
Antibody-drug conjugates (ADCs), Targeted drug delivery, ADC design optimization, Clinical trial termination factors.
Esophageal cancer, Gastroesophageal reflux disease, Global burden of disease, Time-series modeling and forecasting, Risk factor clustering, Temporal association analysis
Rare tumors, Incidence rate, Cancer survival, Cancer burden, China
non-small-cell lung cancer, neoadjuvant, camrelizumab, apatinib, survival